Technology ❯ Biotechnology ❯ mRNA Technology

Vaccine Development

Clinical Trials Moderna COVID-19 Vaccines Cancer Vaccines Public Health Innovations Regulatory Approval Clinical Research Covid-19 Vaccines mRNA Vaccines Flu Vaccine Medical Applications Cancer Treatments Emerging Infectious Diseases AI in Medicine Scientific Innovation Patent Conflicts Curevac Cancer Treatment Health Innovations

46 ARTICLES

last mo.

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

The authorization brings the first U.S.‑licensed mRNA seasonal flu vaccine but its public rollout is uncertain because the CDC advisory panel cannot meet to set formal recommendations.

3 ARTICLES

last mo.

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

8 ARTICLES

last yr.

US Cuts $500 Million in mRNA Vaccine Research Funding

5 ARTICLES

last yr.

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

Vaccine Development

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

Moderna Posts Q2 Revenue Beat as Norovirus Trial Misses Interim Goal

FDA Advisers Unanimously Back Moderna’s mRNA Flu Vaccine

Moderna Jumps on Hantavirus Cruise-Ship Cluster as U.S. Repatriates 17 Citizens

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

US Cuts $500 Million in mRNA Vaccine Research Funding

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial